Blogs

Explore how the BUMHI initiative advances urban mental health through research, evidence-based action, and community impact to build healthier cities.

Reduce CoG by using design of experiments, quality by design, and smart tech transfer in early development. Practical strategies to cut cost without risk.

Peptide synthesis and the hidden complexities of scaling peptide therapeutics, from SPPS to purification, analytics, and cGMP manufacturing. Talk to our team today.

Discover how Project Optimus is changing oncology drug development through data-driven dose optimization and modeling strategies. Learn more today.

Peptide synthesis and the hidden complexities of scaling peptide therapeutics, from SPPS to purification, analytics, and cGMP manufacturing. Talk to our team today.

CPHI Frankfurt 2025 is the year’s most efficient place to compare science, scale, and reliability in one hall. Sponsors meet teams, see facilities represented across regions, and validate claims in real time.

OROCIDIN A/S, a company focused on developing a novel treatment for advanced gum disease, or aggressive periodontitis, partnered with Syngene for the synthesis of their lead molecule

Time has always been the most serious concern in drug discovery, making it a race¾ not just to develop new treatments but also to deliver safe and effective medicines to patients more quickly.

One of the less obvious risks in drug development is not how a medicine works inside the body, but how it behaves in the real world, particularly when exposed to sunlight.

India supplies more than 20% of the world’s generic medicines, reaching over 200 countries. It provides 40% of generic drugs used in the U.S. and 80% of antiretrovirals globally, reinforcing its pivotal role in affordable global healthcare.